StreetInsider.com News Articles

enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment

Wed, 15 Jul 2026 08:30:00 -0400

CEO Explains How Broad Patent Protection, Combined with First-Ever FDA IDE Approval, Positions enVVe® to Own a Multi-Billion-Dollar Venous Disease Market

Watch the "What This Means" video here

IRVINE, CA / ACCESS Newswire / July 15, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that Robert Berman, Chief Executive Officer of enVVeno Medical participated in a Virtual Investor "What This Means" segment.

As part of the segment, Mr. Berman discussed the Company's recent news announcing the issuance of the first U.S.

enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment

Wed, 15 Jul 2026 08:30:00 -0400

CEO Explains How Broad Patent Protection, Combined with First-Ever FDA IDE Approval, Positions enVVe® to Own a Multi-Billion-Dollar Venous Disease Market

Watch the "What This Means" video here

As part of the segment, Mr. Berman discussed the Company's recent news announcing the issuance of the first U.S.

Form 8-K enVVeno Medical Corp For: Jul 14

Tue, 14 Jul 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260714/26768889.html

Form 8-K enVVeno Medical Corp For: Jul 14

Tue, 14 Jul 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260714/26768889.html

enVVeno Medical receives first U.S. patent for venous valve system

Tue, 07 Jul 2026 08:29:14 -0400

enVVeno Medical Corporation (NASDAQ: NVNO) announced the issuance of U.S. Patent No. 12,575,932, covering key components of its enVVe transcatheter replacement venous valve system, according to a company press release.

The patent covers the enVVe valve, valve support frame, crimping system, and delivery system, as well as methods for treating patients with deep venous insufficiency (DVI), a condition caused by damaged venous valves that can lead to reflux, venous hypertension, and venous leg ulcers.

The enVVe system is designed as a catheter-based, non-surgical alternative to open surgical venous valve replacement. The company states the system is intended to eliminate the need for

enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial

Tue, 07 Jul 2026 08:29:00 -0400

New Patent Broadly Protects Core Technology Behind Potential First Non-Surgical Replacement Venous Valve

Builds on First-Ever FDA IDE Approval for Pivotal Study of enVVe System Targeting Multi-Billion-Dollar Market Opportunity

enVVe Pivotal Study on Track for Enrollment to Commence and First Patients Data Release Expected by the End of Q4 2026

IRVINE, CA / ACCESS Newswire / July 7, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company") today announced the issuance of U.S. Patent No. 12,575,932, further expanding its intellectual property portfolio supporting its enVVe® transcatheter replacement venous valve system for

enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial

Tue, 07 Jul 2026 08:29:00 -0400

New Patent Broadly Protects Core Technology Behind Potential First Non-Surgical Replacement Venous Valve

Builds on First-Ever FDA IDE Approval for Pivotal Study of enVVe System Targeting Multi-Billion-Dollar Market Opportunity

enVVe Pivotal Study on Track for Enrollment to Commence and First Patients Data Release Expected by the End of Q4 2026

Ladenburg Thalmann Upgrades enVVeno Medical Corp (NVNO) to Buy

Mon, 06 Jul 2026 06:37:09 -0400

Ladenburg Thalmann analyst Jeffrey Cohen upgraded enVVeno Medical Corp (NASDAQ: NVNO) from Neutral to Buy with a price target of $30.00.

For an analyst ratings summary and ratings history on enVVeno Medical Corp click here. For more ratings news on enVVeno Medical Corp click here.

Shares of enVVeno Medical Corp closed at $11.11 yesterday.

enVVeno Medical to Present in the Webull Corporate Connect Webinar Series

Mon, 22 Jun 2026 09:00:00 -0400

- Live webcast on Wednesday, June 24^th at 2:00 PM ET

- Access the event here

IRVINE, CA / ACCESS Newswire / June 22, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"),a company setting new standards of care for the treatment of deep venous disease, today announced that it will present in the Webull Corporate Connect Webinar Series being held virtually June 24-25, 2026.

As part of the discussion, the Company's CEO, Rob Berman, will provide an overview

enVVeno Medical to Present in the Webull Corporate Connect Webinar Series

Mon, 22 Jun 2026 09:00:00 -0400

- Live webcast on Wednesday, June 24^th at 2:00 PM ET

- Access the event here

As part of the discussion, the Company's CEO, Rob Berman, will provide an overview

Form 4 enVVeno Medical Corp For: Jun 11 Filed by: Duhay Francis

Fri, 12 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260612/26640682.html

Form 4 enVVeno Medical Corp For: Jun 11 Filed by: Duhay Francis

Fri, 12 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260612/26640682.html

Form 144 enVVeno Medical Corp Filed by: Duhay Francis

Thu, 11 Jun 2026 11:17:00 -0400

si-local-file:///var/storage/secattach/20260611/26634229.html

Form 144 enVVeno Medical Corp Filed by: Duhay Francis

Thu, 11 Jun 2026 11:17:00 -0400

si-local-file:///var/storage/secattach/20260611/26634229.html

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

Tue, 02 Jun 2026 09:01:00 -0400

Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical, on Tuesday, June 9^that 4:00 PM ET

Register here

IRVINE, CA / ACCESS Newswire / June 2, 2026 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno Medical will participate in a Virtual Investor Closing Bell event on Tuesday, June 9, 2026 at 4:00 PM ET.

As part of the event, Mr.

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

Tue, 02 Jun 2026 09:01:00 -0400

Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical, on Tuesday, June 9^that 4:00 PM ET

Register here

As part of the event, Mr.

Form SCHEDULE 13G/A enVVeno Medical Corp Filed by: PERCEPTIVE ADVISORS LLC

Fri, 15 May 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260515/26504589.html

Form SCHEDULE 13G/A enVVeno Medical Corp Filed by: PERCEPTIVE ADVISORS LLC

Fri, 15 May 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260515/26504589.html

Form SCHEDULE 13G/A enVVeno Medical Corp Filed by: KINGDON CAPITAL MANAGEMENT, L.L.C.

Fri, 15 May 2026 13:34:00 -0400

si-local-file:///var/storage/secattach/20260515/26503345.html

Form SCHEDULE 13G/A enVVeno Medical Corp Filed by: KINGDON CAPITAL MANAGEMENT, L.L.C.

Fri, 15 May 2026 13:34:00 -0400

si-local-file:///var/storage/secattach/20260515/26503345.html

enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment

Tue, 12 May 2026 09:02:00 -0400

First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-surgical Replacement Venous Valve

IDE approval positions enVVeno to advance what could become the first effective treatment option for the approximately 3 million U.S. patients suffering from DVI

Watch the "What This Means" video here

IRVINE, CA / ACCESS Newswire / May 12, 2026 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), today announced that Robert Berman, Chief Executive Officer of enVVeno Medical participated in a Virtual Investor "What This Means" segment.

enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment

Tue, 12 May 2026 09:02:00 -0400

First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-surgical Replacement Venous Valve

IDE approval positions enVVeno to advance what could become the first effective treatment option for the approximately 3 million U.S. patients suffering from DVI

Watch the "What This Means" video here

enVVeno Medical Corporation (NVNO) Misses Q1 EPS by 565c

Thu, 07 May 2026 08:31:40 -0400

enVVeno Medical Corporation (NASDAQ: NVNO) reported Q1 EPS of ($5.89), $5.65 worse than the analyst estimate of ($0.24).

For earnings history and earnings-related data on enVVeno Medical Corporation (NVNO) click here.

enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System

Thu, 07 May 2026 08:05:00 -0400

Company ended the first quarter with approximately $25 million in cash and investments

Capital on hand should fund operations through multiple key milestones into Q3 2027

Company recently received FDA IDE approval to commence TAVVE U.S. Pivotal Study for non-surgical replacement venous valve, enVVe System

TAVVE site selection is underway with patient enrollment expected to commence later this year

IRVINE, CA / ACCESS Newswire / May 7, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today reported financial results for the first quarter 2026, ending the quarter with approximately $25 million in

enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System

Thu, 07 May 2026 08:05:00 -0400

Company ended the first quarter with approximately $25 million in cash and investments

Capital on hand should fund operations through multiple key milestones into Q3 2027

Company recently received FDA IDE approval to commence TAVVE U.S. Pivotal Study for non-surgical replacement venous valve, enVVe System

TAVVE site selection is underway with patient enrollment expected to commence later this year